Tag:
healthcare reform
Latest Headlines
Latest Headlines
George Will jumps on the anti-device tax bandwagon
Washington Post columnist George F. Will says that, unless its repealed, the coming tax on devicemakers will lead to fewer jobs and less innovation.
Congress drags Big Pharma into Obamacare negotiation probe
The House Energy and Commerce Committee has demanded documents and information from five of the top pharma companies.
Lawmakers pressure CMS to get going on doc-disclosure rules
Two senators are pushing regulators to issue rules for complying with the doctor-disclosure provisions of healthcare reform.
Chinese officials intent on 'Anhui model' for price cuts
As China's National People's Congress ends in Beijing, Chinese politicians are repeating their pledge to make healthcare more affordable.
Chinese pharmas feel the squeeze of healthcare reform
Even though China is set to become the second-largest drug market by 2020, all is not rosy for its native drugmakers. A government push to drive down costs for healthcare end users is pressuring pharma companies that call that vast country home, with 5 of them issuing profit warnings in recent weeks.
Should doc-payment rules require more info?
Drug industry leaders fear Sunshine requirements don't go far enough.
Obama budget digs deep into pharma's wallet
The dual-eligibles rebate proposal has surfaced yet again. President Barack Obama's budget proposal includes extending Medicaid-level rebates to the 9 million seniors who qualify for the...
Ex-PhRMA chief's $11.6M tops among healthcare reform lobbyists
Ex-PhRMA chief Billy Tauzin ( photo ) caught a lot of flak in 2010 for brokering an $80 billion cost-savings deal with President Barack Obama, helping the administration seal its healthcare reform
Obama plan hits pharma with rebates, pay-to-delay ban
President Obama's deficit-cutting plan hits pharma with a one-two-three punch. As he's advocated before, Obama would impose higher drug rebates on dual-eligibles, the low-income Medicare patients who
Obama deficit plan rolls back biotech marketing exclusivity to 7 years
The healthcare reform bill contained plenty of pain for the pharma world, which had to make some big concessions on drug costs for federal health programs. But it also contained some nuggets of pure
